NeOnc Technologies Holdings Inc Dossier - Source-backed chat

NeOnc Technologies Holdings Inc

NTHINASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.74

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.06Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $88.1M

Enterprise Value $86.5M

Shares Outstanding 27.4M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) is a clinical-stage biopharmaceutical company positioned at a pivotal inflection point in neuro-oncology. By developing proprietary, brain-penetrant therapeutics designed to bypass the blood-brain barrier, NeOnc addresses a critical unmet need in central nervous system (CNS) cancers. The company's lead candidate, NEO100 (intranasal purified perillyl acid), has completed Phase 2a enrollment for recurrent IDH1-mutant high-grade glioma, with highly anticipated preliminary data expected in August 2026. Its second candidate, NEO212 (an oral chemical conjugate), has successfully completed Phase 1 dose escalation, establishing a recommended Phase 2 dose of 610 mg. Backed by strong insider buying from the CEO and a recent $10 million PIPE financing, NeOnc offers a high-risk, high-reward opportunity ahead of major clinical and regulatory catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$13.00

Mean target$16.00

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$13.0020%

The bear case is triggered by disappointing or ambiguous preliminary data from the NEO100 Phase 2a trial, or safety/toxicity concerns emerging under chronic dosing. Furthermore, if the FDA requires extensive, costly additional trials for NEO212 rather than an accelerated registrational path, the timeline to commercialization will be severely delayed. Combined with a short cash runway extending only into September 2026, failure to secure dilutive-free financing would lead to severe equity dilution or operational distress.

Base CaseCentral scenario

$16.0050%

Matches the consensus mean

The base case assumes NEO100 Phase 2a preliminary data aligns with previous positive trends, demonstrating therapeutic benefit superior to historical salvage therapies (~8% remission). The FDA agrees to a standard registrational Phase 2 design for NEO212 during the End-of-Phase 1 meeting. The company successfully raises additional capital or executes strategic licensing deals to extend its cash runway past September 2026, supporting steady progression of its clinical pipeline.

Bull CaseUpside scenario

$20.0030%

The bull case is driven by outstanding clinical efficacy in the upcoming NEO100 Phase 2a readout in August 2026, confirming or exceeding the 24% radiographic remission rate and 44% six-month PFS observed in earlier cohorts. Additionally, a successful Type B End-of-Phase 1 meeting with the FDA for NEO212 establishes a clear, accelerated path toward a registrational Phase 2 trial. Rapid clinical progress in the Middle East via the NuroMENA joint venture and UAE IND approval further expands the global addressable market, attracting major institutional backing and strategic pharmaceutical partnerships.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Targeted CNS Delivery: Proprietary intranasal (NEO100) and oral conjugate (NEO212) platforms successfully bypass the blood-brain barrier, a major historical obstacle in brain cancer treatment.
Strong Preliminary Efficacy: NEO100 has demonstrated a 24% radiographic remission rate in recurrent IDH1-mutant gliomas, three times higher than historical salvage therapy benchmarks (~8%).
Imminent Clinical Catalysts: Fully enrolled NEO100 Phase 2a trial is on track for a preliminary data readout in August 2026, representing a near-term valuation inflection point.
Aligned Management: Significant insider buying, including over $500,000 in stock purchases by the Chairman and CEO in mid-2026, signals strong internal conviction.
Global Expansion: Recent UAE IND clearance for NEO212 and the NuroMENA joint venture establish an international clinical and commercial pathway.

Key Investment Risks

Clinical Trial Failure: As a clinical-stage biotech, any failure to meet primary efficacy or safety endpoints in upcoming trials would severely impact valuation.
Short Cash Runway: Current cash reserves are projected to fund operations only into September 2026, necessitating near-term capital raises or partnerships.
Regulatory Hurdles: Delays or unfavorable outcomes from the upcoming Type B End-of-Phase 1 FDA meeting for NEO212 could prolong development timelines.
High Volatility: As a micro-cap stock with a high beta (~2.89 to 3.19), NTHI is subject to extreme price fluctuations and limited trading liquidity.

Thesis Invalidation Triggers

Failure of NEO100 Phase 2a trial to demonstrate a statistically significant improvement in radiographic remission or progression-free survival compared to historical controls.
Inability to secure additional financing or strategic partnerships before September 2026, resulting in a severe going-concern risk or highly dilutive equity issuance.
The FDA refusing to support an accelerated or registrational Phase 2 pathway for NEO212 during the End-of-Phase 1 meeting.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.